AU2009290543B2 - PD-1 specific antibodies and uses thereof - Google Patents

PD-1 specific antibodies and uses thereof Download PDF

Info

Publication number
AU2009290543B2
AU2009290543B2 AU2009290543A AU2009290543A AU2009290543B2 AU 2009290543 B2 AU2009290543 B2 AU 2009290543B2 AU 2009290543 A AU2009290543 A AU 2009290543A AU 2009290543 A AU2009290543 A AU 2009290543A AU 2009290543 B2 AU2009290543 B2 AU 2009290543B2
Authority
AU
Australia
Prior art keywords
seq
antibody
antibodies
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009290543A
Other languages
English (en)
Other versions
AU2009290543A2 (en
AU2009290543A1 (en
Inventor
Simon Davis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Publication of AU2009290543A1 publication Critical patent/AU2009290543A1/en
Publication of AU2009290543A2 publication Critical patent/AU2009290543A2/en
Application granted granted Critical
Publication of AU2009290543B2 publication Critical patent/AU2009290543B2/en
Assigned to OXFORD UNIVERSITY INNOVATION LIMITED reassignment OXFORD UNIVERSITY INNOVATION LIMITED Request to Amend Deed and Register Assignors: ISIS INNOVATION LIMITED
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2009290543A 2008-09-12 2009-09-14 PD-1 specific antibodies and uses thereof Active AU2009290543B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9644708P 2008-09-12 2008-09-12
US61/096,447 2008-09-12
PCT/IB2009/006940 WO2010029434A1 (en) 2008-09-12 2009-09-14 Pd-1 specific antibodies and uses thereof

Publications (3)

Publication Number Publication Date
AU2009290543A1 AU2009290543A1 (en) 2010-03-18
AU2009290543A2 AU2009290543A2 (en) 2011-04-28
AU2009290543B2 true AU2009290543B2 (en) 2015-09-03

Family

ID=41335564

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009290543A Active AU2009290543B2 (en) 2008-09-12 2009-09-14 PD-1 specific antibodies and uses thereof

Country Status (6)

Country Link
US (1) US9181342B2 (enExample)
EP (1) EP2342228B1 (enExample)
JP (1) JP5794917B2 (enExample)
AU (1) AU2009290543B2 (enExample)
CA (1) CA2736816C (enExample)
WO (1) WO2010029434A1 (enExample)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2445932B1 (en) 2009-06-26 2018-02-28 Soricimed Biopharma Inc. Soricidin derived peptides and methods for the detection of trpv-6 cancers and drug delivery
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CA2791930A1 (en) 2010-03-11 2011-09-15 Kerry Louise Tyson Pd-1 antibody
ES2669310T3 (es) * 2011-04-20 2018-05-24 Medimmune, Llc Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1
US10981969B2 (en) * 2011-07-29 2021-04-20 The Trustees Of The University Of Pennsylvania Switch costimulatory receptors
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
SG11201508528TA (en) 2013-05-02 2015-11-27 Anaptysbio Inc Antibodies directed against programmed death-1 (pd-1)
PL3444271T3 (pl) 2013-08-08 2022-03-07 Cytune Pharma Modulokiny oparte na il-15 i domenie sushi il-15ralfa
EP3659622A1 (en) 2013-08-08 2020-06-03 Cytune Pharma Combined pharmaceutical composition
PT3702373T (pt) 2013-09-13 2022-09-27 Beigene Switzerland Gmbh Anticorpos anti-pd1 e a sua utilização como agentes terapêuticos e de diagnóstico
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CA2936962C (en) 2014-03-14 2024-03-05 Novartis Ag Antibody molecules to lag-3 and uses thereof
JP6526189B2 (ja) 2014-07-03 2019-06-05 ベイジーン リミテッド 抗ｐｄ−ｌ１抗体並びにその治療及び診断のための使用
EP3171892B1 (en) 2014-07-22 2021-11-24 Apollomics Inc. Anti-pd-1 antibodies
US9982052B2 (en) * 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
PL3177644T3 (pl) * 2014-08-05 2021-06-14 MabQuest SA Immunologiczne reagenty wiążące do PD-1
RU2722212C9 (ru) 2014-08-05 2020-07-23 СиБи ТЕРЕПЬЮТИКС, ИНК. Анти-pd-l1 антитела
CA2960824A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
IL251669B2 (en) 2014-10-10 2023-02-01 Idera Pharmaceuticals Inc Cancer treatment using a tlr9 agonist with checkpoint inhibitors
TWI683667B (zh) 2014-10-21 2020-02-01 開曼群島商賽生製藥國際有限公司 用免疫刺激物治療癌症
EP3223845B1 (en) 2014-11-26 2021-05-19 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd20
IL303905A (en) 2015-05-18 2023-08-01 Tcr2 Therapeutics Inc Compositions and methods for TCR programming using fusion proteins
US10874724B2 (en) * 2015-05-22 2020-12-29 University Of Houston System Enzymatic immunomodulation of solid tumors and uses thereof
US10513558B2 (en) 2015-07-13 2019-12-24 Cytomx Therapeutics, Inc. Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof
MA42459A (fr) 2015-07-16 2018-05-23 Bioxcel Therapeutics Inc Nouvelle approche pour le traitement du cancer par immunomodulation
KR20180036996A (ko) 2015-08-04 2018-04-10 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 조합 치료 및 그의 용도 및 방법
EP3331918A1 (en) 2015-08-04 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Combination treatments and uses and methods thereof
US20180230431A1 (en) 2015-08-07 2018-08-16 Glaxosmithkline Intellectual Property Development Limited Combination Therapy
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
KR20220131277A (ko) 2015-09-01 2022-09-27 아게누스 인코포레이티드 항-pd-1 항체 및 이를 이용하는 방법
EP3355920A4 (en) 2015-09-29 2019-05-15 Celgene Corporation PD-1 BINDING PROTEINS AND METHOD OF USE THEREOF
US12030942B2 (en) 2015-10-02 2024-07-09 Les Laboratoires Servier Anti-PD-1 antibodies and compositions
MY190324A (en) 2015-10-02 2022-04-14 Symphogen As Anti-pd-1 antibodies and compositions
RS62258B1 (sr) 2015-10-02 2021-09-30 Hoffmann La Roche Bispecifična antitela specifična za pd1 i tim3
MA43018B1 (fr) 2015-10-02 2021-11-30 Hoffmann La Roche Anticorps anti-pd1 et procédés d'utilisation
BR112018008891A8 (pt) 2015-11-03 2019-02-26 Janssen Biotech Inc anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
BR112018012801B1 (pt) 2015-12-22 2024-03-12 Regeneron Pharmaceuticals, Inc Usos de uma combinação de anticorpos anti-pd-1 e anticorpos biespecíficos anti-cd20/anti-cd3 e de uma composição farmacêutica
WO2017125815A2 (en) 2016-01-22 2017-07-27 MabQuest SA Immunological reagents
US10947317B2 (en) 2016-03-15 2021-03-16 Mersana Therapeutics, Inc. NaPi2b-targeted antibody-drug conjugates and methods of use thereof
US11760803B2 (en) 2016-03-24 2023-09-19 Takeda Pharmaceutical Company Limited Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
TWI786044B (zh) 2016-05-13 2022-12-11 美商再生元醫藥公司 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
EP3243832A1 (en) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
CN106008714B (zh) * 2016-05-24 2019-03-15 瑞阳(苏州)生物科技有限公司 抗人pd-1人源化单克隆抗体及其应用
WO2017218707A2 (en) * 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
CN109475536B (zh) 2016-07-05 2022-05-27 百济神州有限公司 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合
EP3494140A1 (en) 2016-08-04 2019-06-12 GlaxoSmithKline Intellectual Property Development Ltd Anti-icos and anti-pd-1 antibody combination therapy
CN118252927A (zh) 2016-08-19 2024-06-28 百济神州有限公司 使用包含btk抑制剂的组合产品治疗癌症
AU2017329024A1 (en) 2016-09-19 2019-03-21 Celgene Corporation Methods of treating immune disorders using pd-1 binding proteins
US10766958B2 (en) 2016-09-19 2020-09-08 Celgene Corporation Methods of treating vitiligo using PD-1 binding antibodies
CN107840887B (zh) * 2016-09-21 2022-03-25 基石药业（苏州）有限公司 一种新的pd-1单克隆抗体
CA3039774A1 (en) 2016-10-10 2018-04-19 The National Institute for Biotechnology in the Negev Ltd. Non-cytotoxic modified cells and use thereof
MA49863A (fr) 2016-11-01 2020-06-17 Anaptysbio Inc Anticorps dirigés contre la mort programmée 1 (pd -1)
UY37463A (es) 2016-11-02 2018-05-31 Glaxosmithkline Ip No 2 Ltd Proteínas de unión
WO2018091661A1 (en) 2016-11-18 2018-05-24 Symphogen A/S Anti-pd-1 antibodies and compositions
AU2017363311A1 (en) 2016-11-22 2019-06-13 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
WO2018100535A1 (en) 2016-12-01 2018-06-07 Glaxosmithkline Intellectual Property Development Limited Combination therapy
JP2020500878A (ja) 2016-12-01 2020-01-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 併用療法
CA3046082A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Antibodies and methods of use thereof
PL3565844T3 (pl) 2017-01-09 2023-06-12 Tesaro Inc. Sposoby leczenia nowotworów złośliwych przeciwciałami anty-pd-1
WO2018137681A1 (en) 2017-01-25 2018-08-02 Beigene, Ltd. Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof
WO2018150326A1 (en) 2017-02-15 2018-08-23 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
US20180271996A1 (en) 2017-02-28 2018-09-27 Mersana Therapeutics, Inc. Combination therapies of her2-targeted antibody-drug conjugates
CA3056630A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
JP7426825B2 (ja) 2017-04-03 2024-02-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｐｄ－１抗体と突然変異ｉｌ－２とまたはｉｌ－１５とのイムノコンジュゲート
US11285207B2 (en) 2017-04-05 2022-03-29 Hoffmann-La Roche Inc. Bispecific antibodies specifically binding to PD1 and LAG3
AU2018247916B2 (en) 2017-04-05 2025-04-24 Les Laboratoires Servier Combination therapies targeting PD-1, TIM-3, and LAG-3
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
WO2018226580A2 (en) 2017-06-05 2018-12-13 Janssen Biotech, Inc. Antibodies that specifically bind pd-1 and methods of use
WO2018225033A1 (en) 2017-06-09 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy
JP2020525411A (ja) 2017-06-26 2020-08-27 ベイジーン リミテッド 肝細胞癌のための免疫療法
BR112020000228A2 (pt) 2017-07-06 2020-07-14 Merus N.V. anticorpos que modulam uma atividade biológica expressa por célula
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
WO2019104289A1 (en) 2017-11-27 2019-05-31 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
WO2019108795A1 (en) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3727463A1 (en) 2017-12-21 2020-10-28 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
WO2019149716A1 (en) 2018-01-31 2019-08-08 F. Hoffmann-La Roche Ag Bispecific antibodies comprising an antigen-binding site binding to lag3
AR114127A1 (es) * 2018-03-02 2020-07-22 Lilly Co Eli Anticuerpos agonistas contra pd-1 y usos de estos
US20210363216A1 (en) 2018-05-14 2021-11-25 Immunocore Limited Bifunctional binding polypeptides
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
WO2020030571A1 (en) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combinations of a pd-1 antibody and a tlr4 modulator and uses thereof
WO2020086476A1 (en) 2018-10-22 2020-04-30 Glaxosmithkline Intellectual Property Development Limited Dosing
EP3873534A1 (en) 2018-10-29 2021-09-08 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
CA3119311A1 (en) 2018-11-09 2020-05-14 Pierian Biosciences, LLC Methods and compositions for determining the composition of a tumor microenvironment
GB201820547D0 (en) * 2018-12-17 2019-01-30 Oxford Univ Innovation Modified antibodies
EP3924521A4 (en) 2019-02-15 2023-03-29 IncellDx, Inc. Assaying bladder-associated samples, identifying and treating bladder-associated neoplasia, and kits for use therein
WO2020214957A1 (en) * 2019-04-19 2020-10-22 Tcrcure Biopharma Corp. Anti-pd-1 antibodies and uses thereof
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
CA3141327A1 (en) 2019-05-20 2020-11-26 Pandion Operations, Inc. Madcam targeted immunotolerance
CA3142714A1 (en) * 2019-06-05 2020-12-10 Anaptysbio, Inc. Pd-1 agonist and method of using same
US20210038684A1 (en) 2019-06-11 2021-02-11 Alkermes Pharma Ireland Limited Compositions and Methods for Cancer Immunotherapy
US20220233685A1 (en) 2019-06-18 2022-07-28 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
EP3986454A1 (en) 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
US20220372148A1 (en) 2019-07-05 2022-11-24 Ono Pharmaceutical Co., Ltd. A pharmaceutical composition for treating hematological cancer
WO2021025140A1 (ja) 2019-08-08 2021-02-11 小野薬品工業株式会社 二重特異性タンパク質
US20220411388A1 (en) 2019-09-17 2022-12-29 Bial - R&D Investments, S.A. Substituted imidazole carboxamides and their use in the treatment of medical disorders
AU2020349519A1 (en) 2019-09-17 2022-03-17 Bial-R&D Investments, S.A. Substituted N-heterocyclic carboxamides as acid ceramidase inhibitors and their use as medicaments
EP4031540A1 (en) 2019-09-17 2022-07-27 Bial-R&D Investments, S.A. Substituted, saturated and unsaturated n-heterocyclic carboxamides and related compounds for their use in the treatment of medical disorders
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
WO2022074464A2 (en) 2020-03-05 2022-04-14 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
CN115698075A (zh) 2020-04-14 2023-02-03 葛兰素史密斯克莱知识产权发展有限公司 涉及抗icos和抗pd1抗体，任选地进一步涉及抗tim3抗体的癌症的组合治疗
WO2021209356A1 (en) 2020-04-14 2021-10-21 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
LT4157876T (lt) 2020-05-26 2024-10-25 Boehringer Ingelheim International Gmbh Anti-pd-1 antikūnai
JP2023532339A (ja) 2020-06-29 2023-07-27 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用
PH12023500013A1 (en) 2020-12-04 2024-03-11 Tidal Therapeutics Inc Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
CA3212665A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
JP2024512669A (ja) 2021-03-31 2024-03-19 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
EP4314062A1 (en) 2021-03-31 2024-02-07 Merus N.V. Novel pd-1 binding domains
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
EP4353746A4 (en) * 2021-06-11 2024-12-04 Guangdong Fapon Biopharma Inc. Anti-pd-1 humanized antibody or antigen-binding fragment thereof and application thereof
CA3224374A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
CN117794953A (zh) 2021-08-03 2024-03-29 豪夫迈·罗氏有限公司 双特异性抗体及使用方法
WO2023028501A1 (en) 2021-08-23 2023-03-02 Immunitas Therapeutics, Inc. Anti-cd161 antibodies and uses thereof
CN118284624A (zh) 2021-11-19 2024-07-02 米罗生物有限公司 Pd-1抗体及其用途
AU2023285094A1 (en) 2022-06-08 2025-01-23 Tidal Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
EP4573125A1 (en) 2022-08-18 2025-06-25 Immunocore Limited Multi-domain binding molecules
IL318931A (en) 2022-08-18 2025-04-01 Immunocore Ltd Multi-domain binding molecules
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024086827A2 (en) 2022-10-20 2024-04-25 Repertoire Immune Medicines, Inc. Cd8 t cell targeted il2
EP4608515A1 (en) 2022-10-25 2025-09-03 Seismic Therapeutic, Inc. Variant igg fc polypeptides and uses thereof
KR20250133728A (ko) 2023-01-06 2025-09-08 라센 테라퓨틱스, 인코포레이티드 항-il-18bp 항체
TW202430560A (zh) 2023-01-06 2024-08-01 美商拉森醫療公司 抗ｉｌ－１８ｂｐ抗體
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
EP4658310A1 (en) 2023-01-30 2025-12-10 Kymab Limited Antibodies
GB202306345D0 (en) 2023-04-28 2023-06-14 Immunocore Ltd Binding molecules
US20240400687A1 (en) 2023-05-10 2024-12-05 Regeneron Pharmaceuticals, Inc. Cd20-pd1 binding molecules and methods of use thereof
WO2024243189A2 (en) * 2023-05-22 2024-11-28 Board Of Regents, The University Of Texas System Antigen binding proteins targeting pd-1
GB202315181D0 (en) 2023-10-03 2023-11-15 Immunocore Ltd Peptide-HLA binding molecules
GB202320012D0 (en) 2023-12-22 2024-02-07 Immunocore Ltd Bispecific molecules
WO2025146662A1 (en) 2024-01-05 2025-07-10 Immunocore Limited Cd1a-pd-1 bispecific agonist for the treatment of atopic dermatitis
WO2025174825A2 (en) 2024-02-12 2025-08-21 Aera Therapeutics, Inc. Delivery compositions
WO2025207705A1 (en) 2024-03-26 2025-10-02 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors
WO2025213154A1 (en) 2024-04-05 2025-10-09 Amgen Inc. Gastrointestinal cancer treatments using mta-cooperative prmt5 inhibitors
WO2025224084A1 (en) 2024-04-22 2025-10-30 Engimmune Therapeutics Ag Proteins comprising t cell receptor constant domains

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056875A1 (en) * 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
US20070202100A1 (en) * 1999-08-23 2007-08-30 Genetics Institute, Llc PD-1, a receptor for B7-4, and uses therefor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5173399A (en) * 1988-06-10 1992-12-22 Abbott Laboratories Mouse monoclonal antibodies to hiv-1p24 and their use in diagnostic tests
CA2105618C (en) * 1992-09-07 2009-11-03 Kazuyasu Nakamura Humanized antibodies to ganglioside gm2
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
EP2439273B1 (en) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
EP3130350A1 (en) 2005-06-08 2017-02-15 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway
JP4777785B2 (ja) 2006-01-31 2011-09-21 独立行政法人科学技術振興機構 ケモカインレセプターｃｃｒ５のｎ末端領域に対する抗体酵素
NZ594510A (en) 2006-12-27 2012-06-29 Harvard College Compositions and methods for the treatment of infections and tumors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202100A1 (en) * 1999-08-23 2007-08-30 Genetics Institute, Llc PD-1, a receptor for B7-4, and uses therefor
WO2004056875A1 (en) * 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SEKO, Y. et al. "Roles of programmed death-1 (PD-1)/PD-1 ligands pathway in the development of murine acute myocarditis caused by coxsackievirus B3." Cardiovascular Research, 07 June 2007. vol. 75, no. 1, pages 158-167. *
WANG, L. et al. "Programmed cell death 1 (PD-1) and its ligand PD-L1 are required for allograft tolerance." European Journal of Immunology, 01 October 2007. vol. 37, no. 10, pages 2983-2990. *

Also Published As

Publication number Publication date
WO2010029434A1 (en) 2010-03-18
JP2012501669A (ja) 2012-01-26
AU2009290543A2 (en) 2011-04-28
JP5794917B2 (ja) 2015-10-14
CA2736816A1 (en) 2010-03-18
EP2342228B1 (en) 2017-09-06
CA2736816C (en) 2018-05-22
AU2009290543A1 (en) 2010-03-18
US20110171220A1 (en) 2011-07-14
EP2342228A1 (en) 2011-07-13
US9181342B2 (en) 2015-11-10

Similar Documents

Publication Publication Date Title
AU2009290543B2 (en) PD-1 specific antibodies and uses thereof
AU2009290544B2 (en) PD-1 specific antibodies and uses thereof
US20230279142A1 (en) Humanized anti-muc1* antibodies
JP6703520B2 (ja) Ｃｄ３イプシロンおよびｂｃｍａに対する二特異性抗体
CA3175979A1 (en) Anti-pd-1 antibodies
CN105531288A (zh) 抗pd1抗体及其作为治疗剂与诊断剂的用途
JP2024522360A (ja) 抗ｃｃｒ８抗体及びその使用
Li et al. Construction and characterization of a humanized anti‐human CD3 monoclonal antibody 12F6 with effective immunoregulation functions
US20250129177A1 (en) Combination Therapy Involving Anti-CD39 Antibodies and Anti-PD-1 or Anti-PD-L1 Antibodies
US12258400B2 (en) Antibodies having specificity for BTN2 and uses thereof
WO2023134766A1 (zh) 靶向cd25的抗体及其制备方法和应用
TW202330026A (zh) 用於療法之抗btn3a活化抗體及il2促效劑之組合
JP2023515398A (ja) Ｌｉｌｒｂ３抗体分子およびその使用
RU2849624C2 (ru) Полипептиды, содержащие модифицированный полипептид il-2, и их применения
EP4265639A2 (en) Anti-hvem antibody, and composition and method associated with same
WO2025113640A1 (zh) 结合lilrb1/2或pd1-lilrb1/2的抗体及其用途
WO2025031290A1 (zh) 抗ox40l抗体以及其用途
KR20250075590A (ko) Gcc를 표적으로 하는 항체 및 키메라 항원 수용체 및 이의 사용 방법
KR20240005794A (ko) 항 pd-1 폴리펩티드 및 그의 용도

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 18 MAR 2011

FGA Letters patent sealed or granted (standard patent)